DALLAS – SWK Holdings Company (NASDAQ:SWKH), a specialty finance firm centered on the life sciences sector, has introduced a number of monetary transactions and updates to its portfolio since September 30, 2024. With a market capitalization of $196 million and a powerful gross revenue margin of 91%, InvestingPro information reveals the corporate maintains robust monetary well being with a strong present ratio of 57.7. The corporate has engaged in new funding agreements, obtained repayments from numerous debtors, and expanded present credit score services.
In a sequence of funding actions, SWK superior $5.0 million to Journey Medical (TASE:) in November to assist the launch of EmrosiTM and offered $0.6 million to Biotricity, acquiring 600,000 inventory warrants. December noticed SWK shut an $8.0 million mortgage with Triple Ring Applied sciences and lengthen $2.5 million to SKNV and MedMinder, present debtors. Moreover, SWK expanded its credit score facility with Eton Prescribed drugs (NASDAQ:) from $4.3 million to $30.0 million, receiving extra inventory warrants. In keeping with InvestingPro evaluation, the corporate’s robust liquidity place and worthwhile operations assist its lively lending technique. Subscribers can entry detailed monetary well being metrics and extra ProTips on the platform.
On the compensation entrance, SWK obtained a internet cost of $3.4 million from the sale of Exeevo belongings in November, adopted by a $0.7 million cost in early January, with an extra $0.5 million anticipated within the first quarter of 2025. The corporate additionally obtained $13.0 million from the Biolase (OTC:) chapter property and anticipates one other cost within the first half of 2025. Funds of $1.9 million from Trio Healthcare and $4.2 million from Veru (NASDAQ:) have been obtained in December. Moleculight made a ultimate cost of $12.2 million to SWK in January, clearing its obligations, though SWK continues to carry most popular fairness in Moleculight.
SWK Holdings focuses on offering non-dilutive financing options to healthcare corporations to assist the event and commercialization of medical applied sciences and merchandise. Their financing buildings embrace structured debt, royalty monetization, artificial royalty transactions, and asset purchases. Buying and selling at $16.04, InvestingPro evaluation signifies the inventory is at present barely overvalued based mostly on their proprietary Honest Worth mannequin. For complete insights, together with detailed valuation metrics and skilled evaluation, buyers can entry the total Professional Analysis Report, out there for over 1,400 US shares on the platform.
The corporate additionally owns Enteris BioPharma, which presents improvement companies and oral drug supply applied sciences to pharmaceutical companions. The data shared is predicated on the corporate’s newest press launch and is introduced with out endorsement of the claims. Buyers are suggested that forward-looking statements contain dangers and uncertainties that will have an effect on the corporate’s monetary outcomes.
This text was generated with the assist of AI and reviewed by an editor. For extra info see our T&C.
